


## GSK2593074A

Cat. No.:	HY-122909
CAS No.:	1337531-06-2
Molecular Formula:	C <sub>27</sub> H <sub>23</sub> N <sub>5</sub> OS
Molecular Weight:	465.57
Target:	RIP kinase
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the COA.



### BIOLOGICAL ACTIVITY

<b>Description</b>	GSK2593074A (GSK'074) is a <b>necroptosis</b> inhibitor with dual targeting ability to both <b>RIP1</b> and <b>RIP3</b> <sup>[1]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	RIP1, RIP3 <sup>[1]</sup>								
<b>In Vitro</b>	<p>GSK2593074A (GSK'074; 0.01, 0.1, 1, 10, and 100 nM; 6 hours for MOVAS cells; 3 hours for L929 cells) completely rescues cells from necroptosis under different stimuli in both human and murine cells at IC<sub>50</sub>~3 nM. In multiple cell types including mouse SMCs, fibroblasts (L929), bone marrow derived macrophages (BMDM), and human colon epithelial cells (HT29), GSK2593074A inhibits necroptosis with an IC<sub>50</sub> of ~3 nM<sup>[1]</sup>.</p> <p><b>Cell Viability Assay</b><sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>Mouse smooth muscle cell line MOVAS; Mouse fibroblast cell line L929</td> </tr> <tr> <td>Concentration:</td> <td>0.01, 0.1, 1, 10, and 100 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>6 hours for MOVAS cells; 3 hours for L929 cells</td> </tr> <tr> <td>Result:</td> <td>Inhibited MOVAS and L929 cells with the IC<sub>50</sub> of 3 nM.</td> </tr> </table>	Cell Line:	Mouse smooth muscle cell line MOVAS; Mouse fibroblast cell line L929	Concentration:	0.01, 0.1, 1, 10, and 100 nM	Incubation Time:	6 hours for MOVAS cells; 3 hours for L929 cells	Result:	Inhibited MOVAS and L929 cells with the IC <sub>50</sub> of 3 nM.
Cell Line:	Mouse smooth muscle cell line MOVAS; Mouse fibroblast cell line L929								
Concentration:	0.01, 0.1, 1, 10, and 100 nM								
Incubation Time:	6 hours for MOVAS cells; 3 hours for L929 cells								
Result:	Inhibited MOVAS and L929 cells with the IC <sub>50</sub> of 3 nM.								
<b>In Vivo</b>	<p>GSK2593074A (GSK'074; 0.93 mg/kg/day; i.p. injection; 14 or 28 days) is administrated to Apoe<sup>-/-</sup> mice immediately following pump implantation. Compared to the DMSO group, GSK2593074A-treated mice show significantly alleviated aneurysm formation, reflected by a much smaller aortic dilatation (DMSO 85.39±15.76% vs GSK2593074A 36.28±5.76%; P&lt;0.05) as well as a reduced abdominal aortic aneurysm (AAA) incidence (from 83.3 to 16.7%). GSK2593074A significantly decreases the extent of aortic expansion (DMSO 66.06±9.17% vs GSK2593074A 27.36±8.25%; P&lt;0.05) <sup>[1]</sup>.</p> <table border="1"> <tr> <td><b>Animal Model:</b></td> <td>Apoe<sup>-/-</sup> female mice (9-10 months)<sup>[1]</sup></td> </tr> <tr> <td><b>Dosage:</b></td> <td>0.93 mg/kg/day; 200 μL</td> </tr> <tr> <td><b>Administration:</b></td> <td>Daily i.p. injection; 14 or 28 days</td> </tr> <tr> <td><b>Result:</b></td> <td>Inhibited aneurysm formation in mouse models of aneurysms.</td> </tr> </table>	<b>Animal Model:</b>	Apoe <sup>-/-</sup> female mice (9-10 months) <sup>[1]</sup>	<b>Dosage:</b>	0.93 mg/kg/day; 200 μL	<b>Administration:</b>	Daily i.p. injection; 14 or 28 days	<b>Result:</b>	Inhibited aneurysm formation in mouse models of aneurysms.
<b>Animal Model:</b>	Apoe <sup>-/-</sup> female mice (9-10 months) <sup>[1]</sup>								
<b>Dosage:</b>	0.93 mg/kg/day; 200 μL								
<b>Administration:</b>	Daily i.p. injection; 14 or 28 days								
<b>Result:</b>	Inhibited aneurysm formation in mouse models of aneurysms.								

---

## REFERENCES

---

[1]. Zhou T, et al. Identification of a novel class of RIP1/RIP3 dual inhibitors that impede cell death and inflammation in mouse abdominal aortic aneurysm models. Cell Death Dis. 2019 Mar 6;10(3):226.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA